间充质干细胞微泡对ARDS肺纤维化影响的实验研究

doi:10.3877/cma.j.issn.1674-0785.2024.01.011

目的

明确间充质干细胞微泡（MSC-MVs）对急性呼吸窘迫综合征（ARDS）肺纤维化小鼠肺纤维化的影响。

方法

采用慢病毒转染技术获取肝细胞生长因子（HGF）低表达的MSC-MVs（siHGF-MSC-MVs）；三次注射脂多糖（LPS）法建立ARDS肺纤维化小鼠模型，然后从ARDS肺纤维化小鼠尾静脉注入MSC-MVs或siHGF-MSC-MVs。使用免疫组织化学、western blot、ELISA等方法检测肺纤维化相关蛋白表达，比较MSC-MVs对ARDS肺纤维化小鼠肺纤维化及纤维化相关指标的影响。

结果

ARDS肺纤维化组肺纤维化评分明显高于对照组，MSC-MVs注入肺纤维化小鼠尾静脉后，肺纤维化评分明显降低，然而siHGF-MSC-MVs组肺纤维化评分明显高于MSC-MVs组。与肺纤维化组比较，MSC-MVs组Ⅰ型、Ⅲ型胶原蛋白抗原、TGF-β、α-SMA蛋白表达量明显降低，而siHGF-MSC-MVs组较MSC-MVs组显著增加。ARDS肺纤维化组肺湿/干和Evans蓝漏出量高于对照组，MSC-MVs注射后湿/干和Evans蓝漏出量明显降低，然而，HGF低表达后MSC-MVs的作用被明显抑制。

结论

MSC-MVs部分通过分泌HGF抑制ARDS肺纤维化小鼠肺纤维化。

关键词: 间充质干细胞微泡, 急性呼吸窘迫综合征, 肺纤维化, 肝细胞生长因子

Objective

To investigate the effect of mesenchymal stem cell microvesicles (MSC-MVs) on pulmonary fibrosis in mice with acute respiratory distress syndrome (ARDS).

Methods

MSC-MVs with low expression of hepatocyte growth factor (siHGF-MSC-MVs) were obtained by lentivirus transfection. A mouse model of ARDS pulmonary fibrosis was established by injecting lipopolysaccharide (LPS) three times, and then MSC-MVs or siHGF-MSC-MVs were injected from the tail vein of ARDS mice with pulmonary fibrosis. Immunohistochemistry, Western blot, ELISA, and other methods were used to detect the expression of pulmonary fibrosis related proteins, and to compare the effects of MSC-MVs on pulmonary fibrosis and fibrosis related indicators in ARDS mice with pulmonary fibrosis.

Results

The pulmonary fibrosis score in the pulmonary fibrosis group was significantly higher than that of the control group. After MSC-MVs were injected into the tail vein of pulmonary fibrosis mice, the pulmonary fibrosis score was significantly reduced. However, the siHGF-MSC-MVs group had a significantly higher pulmonary fibrosis score than the MSC-MVs group. Compared with the pulmonary fibrosis group, the expression levels of type Ⅰ and Ⅲ collagen antigens, TGF-β, α-SMA protein were significantly reduced in the MSC-MVs group, while these indicators significantly increased in the siHGF-MSC-MVs group compared to the MSC-MVs group. The amount of lung wet/dry and Evans blue leakage in the ARDS pulmonary fibrosis group was higher than that in the control group. After MSC-MVs injection, the wet/dry weight ratio and the amount of Evans blue leakage was significantly reduced. However, the effect of MSC-MVs was significantly inhibited after HGF knockdown.

Conclusion

MSC-MVs inhibit pulmonary fibrosis in ARDS mice partly by secreting HGF.

Key words: Mesenchymal stem cell microvesicles, Acute respiratory distress syndrome, Pulmonary fibrosis, Hepatocyte growth factor

图1 MSC-MVs对ARDS肺纤维化肺损伤的影响。图a为各组肺组织病理切片Masson染色；图b为各组肺损伤评分。与对照组比较，*P<0.05；与肺纤维化比较，^#P<0.05；与MSC-MVs组比较，^&P<0.05

图2 免疫组化检测MSC-MVs对ARDS肺纤维化小鼠肺纤维化相关指标的影响。图a为各组肺组织病理切片免疫组织化学图片；图b为α-SMA蛋白表达量；图c为Ⅰ型胶原蛋白表达量；图d为Ⅲ型胶原蛋白表达量；图e为TGF-β蛋白表达量。与对照组比较，*P<0.05；与肺纤维化比较，^#P<0.05；与MSC-MVs组比较，^&P<0.05

图3 Western Blot检测MSC-MVs对ARDS肺纤维化小鼠肺纤维化相关蛋白的影响。图a为各组肺组织纤维化相关蛋白的western blot条带图；图b为各纤维化相关蛋白相对表达量。与对照组比较，*P<0.05；与肺纤维化比较，^#P<0.05；与MSC-MVs组比较，^&P<0.05

图4 MSC-MVs对ARDS肺纤维化小鼠肺血管内皮通透性的影响。图a为各组肺湿干重比；图b为Evans蓝检测各组血管内皮通透性。与对照组比较，*P<0.05；与肺纤维化比较，^#P<0.05；与MSC-MVs组比较，^&P<0.05

1	Liu H, Shi Q, Tang L, et al. Apelin-13 ameliorates lps-Induced endothelial-to-mesenchymal transition and post-acute lung injury pulmonary fibrosis by suppressing transforming growth factor-Β1 signaling[J]. Shock, 2023, 59(1): 108-117.
2	Chen QH, Wu F, Liu L, et al. Mesenchymal stem cells regulate the Th17/Treg cell balance partly through hepatocyte growth factor in vitro[J]. Stem cell research & therapy, 2020, 11(1): 91.
3	杨吉林, 吴先正. 间充质干细胞在脓毒症治疗中的研究进展[J/OL]. 中华临床医师杂志(电子版), 2018, 12(9): 525-529.
4	Abreu SC, Lopes-Pacheco M, Weiss DJ, et al. Mesenchymal stromal cell-derived extracellular vesicles in lung diseases: Current status and perspectives[J]. Front Cell Dev Biol, 2021, 9: 600711.
5	Zhang X, Ye L, Tang W, et al. Wnt/β-catenin participates in the repair of acute respiratory distress syndrome-associated early pulmonary fibrosis via mesenchymal stem cell microvesicles[J]. Drug Des Devel Ther, 2022, 16: 237-247.
6	Usunier B, Brossard C, L'Homme B, et al. Hgf and Tsg-6 released by mesenchymal stem cells attenuate colon radiation-induced fibrosis[J]. Int J Mol Sci, 2021, 22(4): 1790.
7	Quesnel C, Marchand-Adam S, Fabre A, et al. Regulation of hepatocyte growth factor secretion by fibroblasts in patients with acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2008, 294(2): L334-L343
8	Wang HW, Zheng RQ, Chen QH, et al. Mesenchymal stem cells microvesicles stabilize endothelial barrier function partly mediated by hepatocyte growth factor (HGF)[J]. Stem Cell Res Ther, 2017, 8(1): 211.
9	Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes[J]. Lancet, 2022 , 400(10358): 1145-1156.
10	Fang XZ, Li M, Wang YX, et al. Mechanosensitive ion channel Piezo1 mediates mechanical ventilation-exacerbated ARDS-associated pulmonary fibrosis[J]. J Adv Res, 2023, 53: 175-186.
11	Wendisch D, Dietrich O, Mari T, et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis[J]. Cell, 2021, 184(26): 6243-6261.
12	Aschner Y, Correll KA, Beke KM, et al. PTPα promotes fibroproliferative responses after acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2022, 323(1): L69-L83.
13	Belén AP, Luis SL, Yuben M, et al. Induced pluripotent stem cell-derived lung alveolar epithelial type II cells reduce damage in bleomycin-induced lung fibrosis[J]. Stem Cell Res Ther, 2020, 11(1): 213.
14	Simone PS, Xiaomei X, Paola C, et al. Anti-fibrotic effects of different sources of MSC in bleomycin-induced lung fibrosis in C57BL6 male mice[J]. Respirology, 2021, 26(2): 161-170.
15	Hu X, Xu Q, Wan H, et al. PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis[J]. Lab Invest, 2020, 100(6): 801-811.
16	Guo Z, Zhang Y, Yan F. Potential of mesenchymal stem cell-based therapies for pulmonary fibrosis[J]. DNA Cell Biol, 2022, 41(11): 951-965.
17	张威, 魏雅楠, 韩娜. 骨髓间充质干细胞来源外泌体对促进大鼠坐骨神经钳夹伤的修复作用[J/OL]. 中华临床医师杂志(电子版), 2021, 15(4): 265-271.
18	Gemayel J, Chaker D, El Hachem G, et al. Mesenchymal stem cells-derived secretome and extracellular vesicles: perspective and challenges in cancer therapy and clinical applications[J]. Clin Transl Oncol, 2023, 25(7): 2056-2068.
19	Gad ES, Salama AA, El-Shafie, et al. The anti-fibrotic and anti-inflammatory potential of Bbone marrow-derived mesenchymal stem cells and nintedanib in bleomycin-induced lung fibrosis in rats[J]. Inflammation, 2020, 43(1): 123-134.
20	Li S, Zhang J, Feng G, et al. The emerging role of extracellular vesicles from mesenchymal stem cells and macrophages in pulmonary fibrosis: Insights into miRNA delivery[J]. Pharmaceuticals (Basel), 2022, 15(10): 1276.
21	Guo Q, Lu Y, Cheng X, et al. Hepatocyte growth factor delivered by nanocomposites for gene therapy of bleomycin-induced pulmonary fibrosis in rats[J]. Curr Drug Deliv, 2023, 20(9): 1368-1379.
22	Chen H, Luo Y, Zhu Y, et al. Enhanced secretion of hepatocyte growth factor in human umbilical cord mesenchymal stem cells ameliorates pulmonary fibrosis induced by bleomycin in rats[J]. Front Pharmacol, 2023, 13: 1070736.
23	Chen WX, Zhou J, Zhou SS, et al. Microvesicles derived from human Wharton's jelly mesenchymal stem cells enhance autophagy and ameliorate acute lung injury via delivery of miR-100[J]. Stem Cell Res Ther, 2020, 11(1): 113.
24	Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine[J]. Stem Cell Res Ther, 2018, 9(1): 63.

[1]	江雅婷, 刘林峰, 沈辰曦, 陈奔, 刘婷, 龚裕强. 组织相关巨噬素3 保护肺血管内皮糖萼治疗急性呼吸窘迫综合征的机制研究[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 353-362.
[2]	李振翮, 魏长青, 甄国栋, 李振富. 脓毒症并发急性呼吸窘迫综合征患者血清S1P、Wnt5a变化及其临床意义[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 293-300.
[3]	杨茂宪, 沈鹏, 王倩倩, 吴旺, 沈永帅, 蒋禛, 徐龙生, 朱建刚, 刘倍倍. 吡啶甲酸镁联合地塞米松对急性呼吸窘迫综合征大鼠的治疗作用研究[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(03): 196-203.
[4]	王亚岚, 倪婧, 余世庆, 陶银花, 张荣. 尼达尼布抗纤维化治疗特发性肺纤维化的耐受性和疗效预测因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 750-755.
[5]	李智, 冯芸. NF-κB 与MAPK 信号通路及其潜在治疗靶点在急性呼吸窘迫综合征中的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 840-843.
[6]	魏丁, 乔艳艳, 顾兴, 张燕, 李艳燕, 钱卫生, 潘蕾, 高永恒, 金发光. 体外膜肺氧合救治急性呼吸窘迫综合征不良预后危险因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 363-367.
[7]	周璇, 谢莉, 邹娟. 尼达尼布对特发性肺纤维化肺功能、肺纤维化程度及PDGF、PGE2、TGF-β1的影响[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 368-372.
[8]	邱凌霄, 王创业, 卿斌, 刘锦程, 张鑫烨, 武文娟, 邢德冰, 郭亮, 徐智, 王斌. 基于转录组学筛选特发性肺纤维化的枢纽基因和信号通路[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 212-217.
[9]	吴沛玲, 娄月妍, 张洪艳, 陈东方, 刘雪青, 赵丽芳, 薛姗, 蒋捍东. 线粒体相关基因在特发性肺纤维化中的分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 178-184.
[10]	王晓霞, 乌丹, 张江英, 乌雅罕, 郝颖楠, 斯日古楞. 《2023 年美国胸科学会关于成人急性呼吸窘迫综合征患者管理的临床实践指南更新》解读[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 338-343.
[11]	杨东星, 沈鹏, 赵慧颖. 免疫球蛋白联合依库珠单抗治疗GBS 并发重度ARDS 患者一例[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 404-408.
[12]	田学, 谢晖, 王瑞兰. 急性呼吸窘迫综合征相关肺纤维化的研究进展[J/OL]. 中华重症医学电子杂志, 2024, 10(03): 258-264.
[13]	李松栗, 黄蔚, 巢杰, 杨毅, 邱海波. 单核/巨噬细胞来源的细胞外囊泡在急性呼吸窘迫综合征中的研究进展[J/OL]. 中华重症医学电子杂志, 2024, 10(03): 253-257.
[14]	杨永红, 杨莹, 齐红蕾, 刘福瑞, 朱金源. 单细胞测序在急性呼吸窘迫综合征中的应用进展[J/OL]. 中华重症医学电子杂志, 2024, 10(03): 248-252.
[15]	倪韫晖, 杨毅, 袁雪燕, 邱海波. 胸壁加压在急性呼吸窘迫综合征中的应用和临床进展[J/OL]. 中华重症医学电子杂志, 2024, 10(03): 243-247.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Effect of mesenchymal stem cell microbubbles on pulmonary fibrosis in mice with acute respiratory distress syndrome: an experimental study

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Effect of mesenchymal stem cell microbubbles on pulmonary fibrosis in mice with acute respiratory distress syndrome: an experimental study